News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novelix Pharmaceuticals Inc. Announces Licensing of Cancer Compound to AOP Orphan Pharmaceuticals AG


2/26/2007 12:48:08 PM

PASADENA, Calif.--(BUSINESS WIRE)--Novelix Pharmaceuticals Inc. (Novelix), a biopharmaceutical company focused on the development of first in class small molecule cancer therapeutics, announced today that it has licensed its drug candidate NVX-207 to AOP Orphan Pharmaceuticals AG. The exclusive but restricted license will enable AOP Orphan Pharmaceuticals to develop and commercialize NVX-207 in human orphan designations in all territories outside the United States. Financial terms of the agreement were not disclosed.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES